Bottom line
PBE vs SHPAX: the short answer
PBE (Invesco Biotechnology & Genome ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 26% of their top holdings (by weight) are shared.
PBE is cheaper at 0.59% vs 3% — a difference of $241 a year per $10,000 invested.
Over five years, PBE returned +3.4% a year vs +3.1% for SHPAX (reporting dates differ).
SHPAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
PBE vs SHPAX side by side
| PBE | SHPAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.59% | 3% |
| Annual cost per $10k | $59 | $300 |
| 10-yr cost on $10k (prospectus) | $738 | $3,702 |
| Max front load | None | 5.75% |
| 12b-1 fee | — | — |
| 1-yr return | +24.7% | −5.5% |
| 5-yr return (annualized) | +3.4% | +3.1% |
| 10-yr return (annualized) | +5.2% | +4.1% |
| Best quarter | +25.3% | +15.0% |
| Worst quarter | −24.3% | −13.0% |
| Net assets (fund) | $281.9M | $10.5M |
| Number of holdings | 33 | 29 |
| Portfolio turnover | 103% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBE | SHPAX | Difference |
|---|---|---|---|
| 2024 | +1.1% | +0.3% | +0.8% |
| 2023 | +3.7% | −0.4% | +4.0% |
| 2022 | −10.8% | +2.0% | −12.8% |
| 2021 | +1.6% | +16.7% | −15.1% |
| 2020 | +25.5% | +3.6% | +21.9% |
| 2019 | +18.3% | +16.2% | +2.1% |
| 2018 | +0.2% | −5.5% | +5.7% |
| 2017 | +22.4% | +12.0% | +10.5% |
| 2016 | −23.0% | −2.0% | −21.1% |
| 2015 | +2.0% | +6.9% | −4.9% |
Source: Fund prospectus bar charts
Holdings overlap
7 of PBE's top 25 holdings also appear in SHPAX's top 25.
| Holding | PBE | SHPAX |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 5.47% | 3.93% |
| Amgen Inc. | 5.22% | 5.04% |
| Vertex Pharmaceuticals Inc. | 4.99% | 3.36% |
| Gilead Sciences, Inc. | 4.43% | 3.94% |
| United Therapeutics Corp. | 4.08% | 6.17% |
| Incyte Corp. | 3.06% | 2.89% |
| Exelixis, Inc. | 2.64% | 4.55% |
Source: SEC Form N-PORT
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between PBE and SHPAX?
Which is cheaper, PBE or SHPAX?
Should I own both PBE and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.